Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC)
Analysts updated ratings for Nektar Therapeutics (NKTR), Roche Holding AG (RHHVF), and Henry Schein (HSIC). UBS gave NKTR a Hold rating with a $53 target; consensus is $132.70. Jefferies maintained a Sell on RHHVF with a CHF250 target; consensus is $444.60. Leerink Partners kept a Hold on HSIC with a $89 target; consensus is $101.23.
How this was made
The 30-second read
Why it matters
New price targets provide fresh valuation benchmarks for NKTR and HSIC, while Roche's rating is omitted due to uncertain ticker.
Market read
Analyst rating updates can prompt short-term trading decisions and affect sector sentiment.
What to watch
Potential upcoming clinical trial results or earnings could quickly change sentiment.
Background
The article aggregates recent analyst rating changes for three healthcare companies.
Ticker impact
UBS issued a Hold rating with a $53 price target for Nektar Therapeutics, new analyst coverage.
likely upward pressure as investors price in the new target.
The $53 target represents a ~28% upside from the $41.17 close, suggesting a bullish bias.
Leerink Partners maintained a Hold rating with a $101.23 price target for Henry Schein, new analyst note.
likely modest upside as the target implies ~20% upside.
The target of $101.23 versus the $84.01 close signals potential upside, supporting buying interest.
Market effects
Analyst rating updates may influence broader healthcare sector sentiment.
US healthcare stocks could see modest movement.
Limited to investors tracking US-listed healthcare equities.
Counterpoint
Some investors may view the Hold ratings as a signal of limited upside despite price targets.
Key entities
- companyNektar Therapeutics
Biopharma firm receiving a Hold rating and $53 target from UBS.
- companyHenry Schein
Medical supplies distributor with a Hold rating and $101.23 target from Leerink.
